Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One...